Best practice & research. Clinical gastroenterology · 2025
Cost-effectiveness of upper endoscopy for gastric cancer screening and surveillance in Western populations.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kapteijn N E A, Mülder D T, Lansdorp-Vogelaar I
Аннотация
BACKGROUND: Gastric cancer (GC) is the fourth leading cause of cancer-related deaths worldwide, with highest incidence rates in Asia. Endoscopic screening may facilitate early detection and reduces mortality, but its cost-effectiveness in Western populations, where GC is less prevalent, remains unclear. This review aimed to evaluate the cost-effectiveness of endoscopic screening and surveillance for GC in Western countries, considering regional epidemiologic and economic differences.
METHODS: A systematic search of literature was conducted using PubMed and Embase databases, focusing on studies evaluating the cost-effectiveness of endoscopy in asymptomatic individuals or high-risk subgroups in Western populations. Studies reporting incremental cost-effectiveness ratios (ICERs) compared to no screening/surveillance were included.
RESULTS: In total fourteen studies were evaluated. Six studies reported on endoscopic screening in the general population, three on screening in high-risk individuals, and seven on endoscopic surveillance, with varying intervals ranging from one-time procedures to procedures every ten years. Endoscopic screening was generally not cost-effective in Western populations. However, screening for high-risk subgroups, or combined with colonoscopy, following a positive fecal immunochemical test, improved cost-effectiveness. Endoscopic surveillance was consistently cost-effective, particularly for individuals with gastric intestinal metaplasia (GIM), showing the best cost-effectiveness at a three-to five-year interval, with ICERs ranging from €18,336 per Quality-Adjusted Life Year (QALY) in Europe to $87,000 per QALY in the USA. For higher-risk lesions, like dysplasia or incomplete GIM, shorter surveillance intervals may be beneficial.
CONCLUSION: While routine endoscopic screening may not be cost-effective in Western populations, surveillance for GIM every three to five years is economically sustainable. Higher-risk individuals with dysplasia or incomplete GIM may benefit from more frequent surveillance.
METHODS: A systematic search of literature was conducted using PubMed and Embase databases, focusing on studies evaluating the cost-effectiveness of endoscopy in asymptomatic individuals or high-risk subgroups in Western populations. Studies reporting incremental cost-effectiveness ratios (ICERs) compared to no screening/surveillance were included.
RESULTS: In total fourteen studies were evaluated. Six studies reported on endoscopic screening in the general population, three on screening in high-risk individuals, and seven on endoscopic surveillance, with varying intervals ranging from one-time procedures to procedures every ten years. Endoscopic screening was generally not cost-effective in Western populations. However, screening for high-risk subgroups, or combined with colonoscopy, following a positive fecal immunochemical test, improved cost-effectiveness. Endoscopic surveillance was consistently cost-effective, particularly for individuals with gastric intestinal metaplasia (GIM), showing the best cost-effectiveness at a three-to five-year interval, with ICERs ranging from €18,336 per Quality-Adjusted Life Year (QALY) in Europe to $87,000 per QALY in the USA. For higher-risk lesions, like dysplasia or incomplete GIM, shorter surveillance intervals may be beneficial.
CONCLUSION: While routine endoscopic screening may not be cost-effective in Western populations, surveillance for GIM every three to five years is economically sustainable. Higher-risk individuals with dysplasia or incomplete GIM may benefit from more frequent surveillance.